David R. Bauer
Lawyers
Filters
Tandem Diabetes Care $316.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029
TruArc Partners acquisition of Meyer Laboratory and $179 million financing
We advised TruArc Partners on the acquisition and related financing arrangements
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Intel $2.55 billion senior notes offering
The senior notes are due 2031, 2034 and 2054
Prime Medicine $161 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Market
Metagenomi $93.75 million IPO
The shares are listed on the Nasdaq Global Market
Tenaya Therapeutics $50 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Gilead Sciences $4.3 billion acquisition of CymaBay Therapeutics
We are advising Gilead Sciences on the acquisition
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064